The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model - PubMed
4 hours ago
- #GLP-1/GIP agonist
- #Parkinson's disease
- #neuroprotection
- The study tests the novel GLP-1/GIP dual receptor agonist DA5-CH against tirzepatide and exendin-4 in a Parkinson's disease (PD) rat model.
- DA5-CH crosses the blood-brain barrier more effectively than tirzepatide and shows superior protection of dopaminergic neurons and normalization of striatal dopamine levels.
- DA5-CH reduces inflammation markers (IL-6, TNF-α) and α-synuclein levels more effectively than exendin-4 and tirzepatide in the PD model.
- The results suggest DA5-CH may be a better therapeutic option for neurodegenerative disorders like PD compared to existing GLP-1 receptor agonists.